The Stock Connect Innovative Drug ETF E Fund (159316) received a net subscription of 12 million units during trading hours.

As of 10:33, the Hang Seng Stock Connect Innovative Drug Index (HSSCID) fell by 1.98%. Among the top ten weighted stocks, Innovent Biologics dropped 1.3%, BeiGene dropped 1.15%, CSPC Pharmaceutical Group dropped 1.29%, Akeso dropped 1.55%, China National Pharmaceutical Group dropped 2.13%, Hansoh Pharmaceutical dropped 2.54%, Sinopharm Group dropped 1.18%, Kelun-Biotech dropped 0.79%, Zai Lab dropped 1.12%, and Conroy Biotech-B dropped 2.35%.

The Hang Seng Stock Connect Innovative Drug ETF E Fund (159316) continues to see capital inflows. As of the previous trading day, the fund had a net inflow of 384 million yuan over the past week, 1.613 billion yuan over the past month, 2.239 billion yuan over the past three months, 2.787 billion yuan over the past six months, and 6.874 billion yuan over the past year. The fund's average daily turnover for the past month was 1.507 billion yuan, ranking first among peers, with active on-exchange trading and strong liquidity. As of press time, the fund received a net subscription of 12 million shares during trading hours.

In terms of news, from January to June this year, the total value of outbound licensing deals for innovative drugs in China was approximately 110 billion US dollars, accounting for 80% of the full-year 2025 total, with 81 transactions, setting a new historical record. The transactions covered 10 areas including oncology, metabolism, and immunity, with licensees from 20 countries and regions.

Recent progress in Business Development (BD) has significantly exceeded expectations. Dizal Pharma secured a $600 million upfront payment for global rights to Suhvotinib from AstraZeneca. Innovent Biologics reached a licensing agreement worth approximately $1.1 billion with Spero Therapeutics. Hansoh Pharmaceutical also received a $120 million upfront payment and high milestone payments for its oral IL-23 project. Research reports indicate that multinational pharmaceutical companies are increasing BD investments due to patent cliffs, while domestic innovative drugs have significantly enhanced their technological competitiveness in areas such as oncology IO2.0, ADC2.0, pan RAS, and autoimmune disease CAR-T. This is the core reason for the continuous high-value realization of BD deals.

A Tianfeng Securities research report believes that under the continued wave of domestic BD transactions, the boom in innovative drug R&D is expected to persist. Tianfeng Securities believes that with sustained hot demand for innovative drug R&D, domestic demand is expected to continue high growth, potentially driving high-speed performance growth across the entire innovative drug industry chain. Attention should be paid to the volume expansion of blockbuster products and corresponding opportunities.

The management fee rate for the Hang Seng Stock Connect Innovative Drug ETF E Fund (159316) is 0.15%, the custody fee rate is 0.05%, and the comprehensive fee rate is 0.2%. The lower fee rates can effectively reduce cost expenditures for investors.

The Hang Seng Stock Connect Innovative Drug ETF E Fund (159316) is currently the only ETF product tracking the Hang Seng Innovative Drug Index in the market, possessing high elasticity and scarcity, helping investors better seize investment opportunities in this round of Hong Kong stock innovative drugs.